<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="vaccines-08-00224-t001" orientation="portrait" position="float">
 <object-id pub-id-type="pii">vaccines-08-00224-t001_Table 1</object-id>
 <label>Table 1</label>
 <caption>
  <p>Critical mechanisms of potential relevance as targets of therapies.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th colspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Immunologic Mechanism Involved in Antiviral Response</th>
    <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Hypothesized Defects Associated with Severe Infection</th>
    <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effect on Antiviral Response</th>
    <th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Proposal of Possible Therapeutic Actions</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Innate immunity</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Early production of IFNs</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Defects in IFN cascade.</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Susceptibility to severe course of herpes, VZV and flu</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Early Type-I IFN administration. Administration of effective antiviral medications</td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activity of natural killer cells</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Defective cytotoxic functions</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary hemophagocytic lymphohistiocytosis. Susceptibility to herpetic viruses.</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Administration of third-party NK. Blockade of lymphohistiocytosis associated cytokine storm</td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Late activation of neutrophils</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased inflammasome signaling</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Possible enhancement of inflammatory response to viruses</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-cytokine biologic agents</td>
   </tr>
   <tr>
    <td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Adaptive immunity</td>
    <td align="left" valign="middle" rowspan="1" colspan="1">Recruitment and expansion of virus-specific CD4 T cells</td>
    <td align="left" valign="middle" rowspan="1" colspan="1">Combined immunodeficiencies with defects in the generation of T-cell and B-cell repertoire</td>
    <td align="left" valign="middle" rowspan="1" colspan="1">Susceptibility to severe infections from various kind of viruses</td>
    <td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Administration of third-party specific lymphocytes. Modulation of thymic function</td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Killing of infected cells by virus-specific CD8 T cells</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Defective cytotoxic functions and defects in generation of T-cell receptor</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Defective response to most viruses</td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Production of antibodies</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Agammaglobulinemia</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not strictly required to overcome the infection. Reduced memory response to new challenges from the same virus</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hyper-immune plasma from recovered subjects</td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Production of ADE-capable antibodies</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased spreading of infection, even to cells not expressing ACE2</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Administration of high dose donor immunoglobulins</td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Production of autoantibodies</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vasculitis</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vascular protection; anticoagulation; immunosuppression</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
